Objectives: To characterize the mechanisms responsible for elevated MICs of ceftaroline for methicillinresistant Staphylococcus aureus (MRSA).
Introduction
Ceftaroline fosamil, the pro-drug of the active metabolite ceftaroline, is a new, broad-spectrum cephalosporin approved in 2010 by the US FDA for the treatment of community-acquired bacterial pneumonia ('CABP') and acute bacterial skin and skin structure infections ('ABSSSIs'). Ceftaroline is active against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Activity against MRSA is a consequence of high binding affinity to penicillin-binding protein (PBP) 2a, 1 the additional PBP protein present in MRSA that confers resistance to other b-lactam antibiotics. 2 Most b-lactam antimicrobial agents have a high affinity for PBP1, 2 and 3, which are essential for staphylococcal cell growth. 3 In addition, ceftaroline has activity against many common wild-type Gram-negative pathogens [i.e. nonextended-spectrum b-lactamase ('non-ESBL')-or AmpC-producing isolates]. 4 As part of the 2008 Assessing Worldwide Antimicrobial Resistance Evaluation ('AWARE') programme, the activities of ceftaroline and comparators were evaluated against consecutive and non-duplicate clinically relevant S. 1 The current study was designed to identify the mechanisms responsible for the decreased susceptibility to ceftaroline in these MRSA clinical isolates.
Materials and methods
The four Greek MRSA strains showing decreased susceptibility to ceftaroline (with MICs of 4 mg/L) were clonally related (two subtypes; similarity coefficient ≥84%) according to PFGE typing results; thus one representative strain (13101) was selected and included in this study. 1 In addition, one strain (4981) displaying the modal ceftaroline MIC value (1 mg/L) found among European MRSA isolates, 1 and another MRSA (4977) showing an MIC result of 2 mg/L were included for comparison purposes. All three selected strains originated from the same Greek medical centre. Two representative strains of international MRSA clones having similar multilocus sequence typing (MLST) and staphylococcal cassette chromosome mec (SCCmec) type results to the evaluated S. aureus isolates were also included for control purposes, as follows: S. aureus N315 (New York/ Japan clone; ST5-MRSA-II; GenBank accession number D86934; ceftaroline MIC 1 mg/L) and S. aureus BAA-39 (Hungarian clone; ST239-MRSA-III; GenBank accession number NZ_AEEK01000041; ceftaroline MIC 1 mg/L).
The three selected clinical strains (13101, 4981 and 4977) were typed by single-locus typing (i.e. spa typing), MLST and by multiple-locus variable-number tandem repeat fingerprinting (MLVF; formerly MLVA), as previously described. 5 -7 In addition, the presence of PantoneValentine leucocidin (PVL) genes (lukF-PV and lukS-PV) and the SCCmec types (I-IV) were determined using a multiplex PCR approach. 8 Custom primers were designed to amplify the entire mecA gene and upstream sequences (promoter and ribosomal binding site regions and mecR1). Amplicons were sequenced on both strands and nucleotide sequences deposited at GenBank under accession numbers JQ582124 (4977), JQ582125 (4981) and JQ582126 (13101). The nucleotide and deduced amino acid sequences were analysed using the Lasergene software package (DNASTAR, Madison, WI, USA). The analysis of ceftaroline and comparator (ceftriaxone and cefotaxime) PBP binding affinities and screening for optimal expression of PBPs among S. aureus isolates, membrane isolation methods, and PBP labelling and competition assays with Bocillin-FL were performed as described previously. 9 Two membrane preparations were made for each isolate. The 50% inhibitory concentration (IC 50 ) was determined as previously described. 9 
Results
Antimicrobial susceptibility profiles for the strains included in this study are shown in Table 1 , while molecular characterization results and IC 50 s for ceftaroline and comparators are displayed in Table 2 . A correlation between the ceftaroline binding affinity for PBP2a and ceftaroline MIC was observed. Ceftaroline demonstrated the highest PBP2a affinity for the S. The affinities of ceftaroline for PBP2a from the tested strains were higher (at least 8-fold) than those of ceftriaxone and cefotaxime (Table 2) . For strain 4981, ceftriaxone (IC 50 8 mg/L) and cefotaxime (IC 50 64 mg/L) showed reduced (128-and 1024-fold, respectively) affinity for PBP2a when compared with ceftaroline (IC 50 0.06 mg/L). In strain 4977, ceftaroline (IC 50 0.25 mg/L) exhibited affinity for PBP2a 8-and 16-fold higher than cefotaxime (IC 50 2 mg/L) and ceftriaxone (IC 50 4 mg/L), respectively. The affinity of ceftaroline for PBP2a of MRSA 13101 was 32-and .128-fold higher than ceftriaxone (IC 50 32 mg/L) and cefotaxime (IC 50 .128 mg/L), respectively.
In Table 2 , the binding affinities of ceftaroline and comparators for PBP1, PBP2, PBP3 and PBP4 are also presented. The IC 50 s for PBP2 and PBP3 are relatively low (ranging from 0.03 to 1 mg/L) for all three drugs for each tested strain. The IC 50 s for PBP1 and PBP4 show greater differences depending on the agent and isolate tested.
Discussion
The ceftaroline PBP2a affinity results for all MRSA strains described here were similar to those previously reported (IC 50 ranged from 0.01 -1 mg/L). 9 In the series of MRSA isolates in the present study showing different ceftaroline MICs, there was an inverse correlation between PBP2a binding affinity and ceftaroline MIC, which is expected because the anti-MRSA activity of ceftaroline reflects binding and inhibition of PBP2a. Isolate 4981, showing a ceftaroline MIC of 1 mg/L, has a wild-type PBP2a amino acid sequence. MRSA strains 4977 and 13101, with increased ceftaroline MICs, demonstrated two mutations (N 146 K and E 150 K) in the nPBD. This region is far from the transpeptidase active site and within a domain not involved in b-lactam binding. 10 However, alterations in this region, including E 150 K, have been indirectly implicated in decreased susceptibility to b-lactam agents, perhaps due to modified protein -protein interactions. Ceftaroline antistaphylococcal activity 1323 JAC anti-MRSA agents) had amino acid substitutions in the penicillinbinding domain of PBP2a. 11, 12 The contribution of the H 351 N substitution to the reduced activity of ceftaroline against strain 13101 is not certain, since other clonally related strains (all also carrying N 146 K and E 150 K) with MIC results of 4 mg/L were found not to contain H 351 N (data not shown). However, it is important to emphasize that b-lactam resistance in S. aureus may also be influenced by other unknown factors within a strain's genetic background. 11, 13 Certainly not all amino acid substitutions in PBP2a are associated with decreased susceptibility to ceftaroline, since amino acid differences at positions 204 and 246 were observed among control strains exhibiting similar ceftaroline MICs. Therefore the effect of the H 351 N substitution on ceftaroline MICs needs further investigation.
In summary, isolates of MRSA with ceftaroline MIC results at ≥4 mg/L are not commonly found. A set of isolates recovered from a single medical centre in Greece with ceftaroline MICs ranging from 1 to 4 mg/L were characterized. Overall, increased ceftaroline MIC results correlated with decreased binding affinity for PBP2a. 9 Alterations have been identified in PBP2a, which appear to have contributed to the reduction in binding affinity and the increase in MIC, albeit further experiments are needed. Moreover, ceftaroline showed good affinity to PBP2 and PBP3 (IC 50 0.25 and 0.25-0.5 mg/L, respectively) among all tested strains.
